Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder

This study has been completed.
Janssen Pharmaceutica
Information provided by (Responsible Party):
Harold W Koenigsberg, Icahn School of Medicine at Mount Sinai Identifier:
First received: September 8, 2005
Last updated: August 2, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2001
  Primary Completion Date: December 2001 (Final data collection date for primary outcome measure)